Navellier & Associates Inc. Sells 157,924 Shares of ADMA Biologics Inc $ADMA

Navellier & Associates Inc. lowered its position in ADMA Biologics Inc (NASDAQ:ADMA) by 92.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,036 shares of the biotechnology company’s stock after selling 157,924 shares during the quarter. Navellier & Associates Inc.’s holdings in ADMA Biologics were worth $176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in the business. Profund Advisors LLC increased its position in ADMA Biologics by 30.4% in the 3rd quarter. Profund Advisors LLC now owns 84,468 shares of the biotechnology company’s stock valued at $1,238,000 after acquiring an additional 19,697 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in shares of ADMA Biologics by 1.7% during the third quarter. Oppenheimer & Co. Inc. now owns 49,230 shares of the biotechnology company’s stock worth $722,000 after purchasing an additional 835 shares during the period. Renaissance Group LLC grew its stake in shares of ADMA Biologics by 50.4% in the third quarter. Renaissance Group LLC now owns 516,588 shares of the biotechnology company’s stock worth $7,573,000 after purchasing an additional 173,016 shares during the last quarter. Homestead Advisers Corp grew its stake in shares of ADMA Biologics by 83.1% in the third quarter. Homestead Advisers Corp now owns 198,500 shares of the biotechnology company’s stock worth $2,910,000 after purchasing an additional 90,100 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in ADMA Biologics by 24.9% in the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after purchasing an additional 826,415 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $16.28 on Thursday. The company’s 50 day moving average price is $18.16 and its 200-day moving average price is $16.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The company has a market capitalization of $3.87 billion, a P/E ratio of 18.93 and a beta of 0.49.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.